Aetion, Inc
Sharon, Connecticut, United States
Jeremy A. Rassen, MS, ScD is a pharmacoepidemiologist with 25 years of academic and industry experience. He is co-founder, president, and chief science officer at Aetion, a healthcare technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies. He leads the Aetion team in their scientific research collaboration with FDA, which uses advanced analytical techniques to answer questions about the use of diagnostics and medications for COVID-19, and risk factors for COVID-19-related complications in patient populations.
Prior to founding Aetion, Dr. Rassen was Assistant Professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. Dr. Rassen frequently speaks and publishes in peer-reviewed publications on how real-world data can be used to measure the safety, effectiveness and value of medications and other treatments.
Before coming to Harvard, Dr. Rassen worked in Silicon Valley at a variety of technology companies, including Hewlett-Packard and Epiphany, Inc. His focus was on high-performance software for the creation and analysis of large databases.
Dr. Rassen is a Fellow of the International Society for Pharmacoepidemiology. He received his bachelor’s degree in Computer Science from Harvard College and his masters and doctorate degrees in Epidemiology from the Harvard T.H. Chan School of Public Health.
Aetion, Inc (Employment, Ownership Interest includes stock, stock options, patent or other intellectual property)
Thursday, August 25, 2022
8:30 AM – 12:30 PM CEST
Thursday, August 25, 2022
2:00 PM – 6:00 PM CEST
Friday, August 26, 2022
5:30 PM – 5:45 PM CEST